ACUTE LEUKEMIAS XVIII
Biology and Treatment Strategies

Munich, Germany - February 20-23, 2022

International Symposium

The next biennial symposium ACUTE LEUKEMIAS XVIII in Munich, Germany, will be postponed to Sunday, February 20 - Wednesday, February 23, 2022

"SAVE THE DATE: ISALXVIII Munich February 20-23, 2022

SPONSORING OPTIONS ACUTE LEUKEMIAS XVIII - 2022 (ISAL XVIII)

General Information and Order Forms

 

Additional Sponsoring Options

Additional Sponsoring Options and Orderforms

Prof. Dr. med.
Wolfgang Hiddemann

Dear Colleagues,
Dear Friends,

It is our great pleasure to invite you to participate in the first hybrid ISAL symposium on ACUTE LEUKEMIAS (ISALXVIII) held in Munich, February 20-23, 2022. While we are optimistic about the recent developments in fighting the pandemic, which will hopefully enable a high level of on-site participation, we are taking into account the current developments and want to be prepared on any changes. We are therefore pleased to inform you that the symposium will be continuing forward as a hybrid meeting.

The aim of this symposium is again to bring together a unique community of clinical scientists and researchers and to discuss the most recent findings in basic research and results of clinical studies and network with the top international experts in these fields.

The scientific program will start on Sunday, February 20, 2022 with a main focus on basic research while the following days will concentrate on translational research and clinical studies. You are cordially invited to use this forum to become updated on recent developments in the complex field of leukemia research and therapy. Satellite Symposia and Meet-the-Expert Sessions will deliver further chances to discuss advances and perspectives of basic science and treatment strategies.

The Symposium will focus on the following key areas:
MS I: Epigenetic Changes in Acute Leukemias
MS II: Clonal Evolution and Leukemic Stem Cells
MS III: Genetic and Molecular Characterization of AML: Novel Markers for Diagnosis and Prognosis
MS IV: Novel Approaches and Targeted Therapies in AML
MS VI: Risk adapted Therapy of AML
MS VII: Biology and Treatment of APL
MS VIII: Relevance of MRD in Acute Leukemias
MS X: Immunotherapy for Acute Leukemias
MS XI: ALL: Biology and Treatment Strategies

Share your research by submitting an abstract for the poster and the best of free contributions sessions. Join us as a Sponsor or Exhibitor and benefit from maximum visibility and exposure to a broad audience.

We look forward to welcoming as many participants as possible in Munich on-site by simultaneously reaching out to a wider and more international audience than ever before.

Yours

Wolfgang Hiddemann
Chairman ISALXVIII 2022